| (Values in U.S. Thousands) | Apr, 2026 | Apr, 2025 | Apr, 2024 | Apr, 2023 | Apr, 2022 |
| Sales | 59,430 | 56,940 | 50,160 | 53,870 | 49,110 |
| Sales Growth | +4.37% | +13.52% | -6.89% | +9.69% | +19.66% |
| Net Income | -1,180 | 4,700 | -7,280 | -5,340 | 550 |
| Net Income Growth | -125.11% | +164.56% | -36.33% | -1,070.91% | +52.78% |
Champions Oncolog (CSBR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland.
Fiscal Year End Date: 04/30